Gabapentin: uses, dosing, side effects & brands

Gabapentin is an anti-epileptic agent used to treat Bipolar Disorder, Partial Epilepsies, Phobic Disorders, Postherpetic Neuralgia.

The FDA classifies gabapentin as an anti-epileptic agent. Anti-epileptic (anticonvulsant) drugs calm the abnormal, excessive electrical activity that triggers seizures. They do this by stabilizing overactive sodium or calcium channels in nerve cells, boosting the brain's natural calming chemical GABA, or dampening excitatory signals, which makes nerves less likely to fire uncontrollably. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

The label states there are no adequate data on the developmental risks of gabapentin in pregnant women. Animal studies (mice, rats, rabbits) showed developmental toxicity — increased fetal skeletal/visceral abnormalities and increased embryofetal mortality — at doses similar to or lower than clinical doses, though the clinical significance is unknown. Because gabapentin is an antiepileptic drug, the label directs pregnant patients to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry (1-888-233-2334). It does not declare the drug safe or unsafe in pregnancy; discuss use with your prescriber. This is what gabapentin's FDA label says; whether to use it in pregnancy is your prescriber's decision.

The label lists weight gain as an adverse reaction. In postherpetic neuralgia trials it reports weight gain in 2% of gabapentin patients vs 0% on placebo, and in adjunctive epilepsy trials 'increased weight' occurred in 3% of adults (vs 2% placebo) and 3% of pediatric patients (vs 1% placebo). These are the label's reported rates, not a folklore claim.

The label addresses alcohol in its Medication Guide, directing patients not to drink alcohol (or take other medicines that cause sleepiness or dizziness) while on gabapentin without first talking with their healthcare provider. The reason given is additive CNS effects: taking gabapentin with alcohol may make sleepiness or dizziness worse. This is consistent with the Warnings section, which notes gabapentin can cause CNS depression and that respiratory depression risk rises when it is combined with other CNS depressants. It is not a disulfiram-like reaction. This is what gabapentin's FDA label says; alcohol advice depends on your dose and health, so confirm with your pharmacist.

The label describes physical dependence and a withdrawal risk (there is no boxed warning). Section 9.3 states physical dependence can develop, with withdrawal signs and symptoms after abrupt discontinuation or significant dose reduction; postmarketing reports named agitation, disorientation, and confusion after suddenly stopping gabapentin, which resolved on restarting. Separately, the Warnings section (Withdrawal-Precipitated Seizure, Status Epilepticus) states antiepileptic drugs should not be abruptly discontinued because seizure frequency may increase. The label directs a prescriber-managed taper: if the dose is reduced, discontinued, or switched to another medication, this should be done gradually over a minimum of one week (a longer period may be needed at the prescriber's discretion). Do not stop gabapentin on your own — any change is a prescriber-managed decision.

The elimination half-life of gabapentin is about 5 to 7 hours in adults with normal kidney function — that is how long the body takes to clear half of a dose. Gabapentin is cleared unchanged by the kidneys and is not appreciably metabolized, so there is no active metabolite and the half-life does not change with dose. However, it lengthens dramatically as kidney function drops — from about 6.5 hours to roughly 52 hours in kidney impairment, and up to about 132 hours in people with no kidney function. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run gabapentin against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

We track 3 gabapentin-containing products in the U.S.: Gabapentin, Gralise and Neurontin. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

Across the brands we track, gabapentin is currently marketed as capsule, solution, suspension and tablet, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Yes. Our catalog lists 1 generic gabapentin product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

The FDA's Enforcement database lists at least 5 recall records whose product description mentions gabapentin. The most recent: Gabapentin Capsules (Oct 10, 2025). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

For nerve pain, gabapentin can take time: the dose is usually titrated up over days to weeks, and it may be several weeks before you reach an effective dose and feel the full benefit. For seizures it also builds over the titration period. Do not stop it abruptly.

Alcohol: the FDA label flags alcohol as something to be careful with — see the alcohol section above for what it actually says. Other medicines: we hold source-cited interaction answers for Can you take gabapentin with ibuprofen?, Can you take gabapentin with Tylenol?, Can you drink alcohol while taking gabapentin? and Can you use weed while taking gabapentin?. This is what the FDA label and our cited sources say — it is not a complete list. Your pharmacist can check your own combination.

Not under federal law — gabapentin is NOT a DEA-scheduled controlled substance nationally. But because of rising misuse, a number of US states (including Alabama, Kentucky, Tennessee, Virginia and West Virginia) have made it a Schedule V controlled substance at the state level, and many more require pharmacies to report it to their prescription-monitoring program. State laws change, so whether it is 'controlled' depends on your state — check locally.

No. 'Narcotic' generally means an opioid, and gabapentin is not an opioid — it is an anticonvulsant (a gabapentinoid) used for seizures and nerve pain. It does not act on opioid receptors. It can, however, cause drowsiness and is sometimes misused alongside opioids, which raises the risk of dangerous breathing problems.

The most common gabapentin side effects are dizziness, drowsiness, and tiredness or weakness — the headline effects that make people feel unsteady or foggy, especially at the start. MedlinePlus also lists unsteadiness, double or blurred vision, uncontrollable shaking (tremor), swelling of the hands, feet, ankles, or lower legs (edema), weight gain, increased appetite, headache, memory problems, nausea, dry mouth, and constipation. Many of these are dose-related and often ease as your body adjusts over the first weeks. Tell your prescriber if any are severe or don't go away — do not stop on your own.

Get emergency help right away for signs of a severe allergic reaction or breathing trouble. MedlinePlus says to call your doctor immediately for: "rash, itching, swelling of the face, throat, tongue, lips, or eyes, hoarseness, difficulty swallowing or breathing, seizures, difficulty breathing; bluish-tinged skin, lips, or fingernails; confusion; or extreme sleepiness." Bluish lips or fingernails, very slow or shallow breathing, or someone being hard to wake are medical emergencies — call 911. Swelling of the face or throat can signal a life-threatening reaction (DRESS/angioedema) and needs immediate care.

Yes. In December 2019 the FDA warned that gabapentin can cause serious, sometimes fatal breathing difficulties in people with respiratory risk factors. The highest-risk groups are people also taking opioids or other central-nervous-system depressants, those with lung conditions such as COPD that reduce breathing, and older adults. In FDA cases reported from 2012–2017, of 49 people with serious breathing problems, 12 died — all had at least one risk factor. Warning signs include confusion, unusual dizziness, extreme sleepiness, slow/shallow/difficult breathing, unresponsiveness, and bluish lips, fingers, or toes. If you take opioids or have a lung condition, this combination should be prescriber-supervised.

It can, in a small number of people. MedlinePlus notes that about 1 in 500 adults and children age 5+ taking anticonvulsants like gabapentin "became suicidal during their treatment." Watch for panic attacks; agitation or restlessness; new or worsening irritability, anxiety, or depression; trouble sleeping; aggressive, angry, or violent behavior; mania; acting on dangerous impulses; withdrawing from friends and family; or talking or thinking about wanting to hurt yourself or end your life. Call your doctor right away — or 988 (Suicide & Crisis Lifeline) — if these appear. Don't stop the medication on your own; your prescriber will manage any change.

Do not stop gabapentin abruptly. MedlinePlus warns that suddenly stopping the tablets, capsules, or oral solution can cause withdrawal symptoms such as anxiety, difficulty falling or staying asleep, nausea, pain, and sweating. Stopping suddenly can also trigger seizures in people who take it for epilepsy. "Do not stop taking gabapentin without talking to your doctor" — instead, "your doctor may decrease your dose gradually over at least a week." With long-term use, the ongoing effects most people report are the dose-related ones — drowsiness, dizziness, unsteadiness, swelling, and weight gain. Any taper should be prescriber-managed.

The sedating effects — dizziness, drowsiness, and unsteadiness — usually show up soon after starting or after a dose increase, which is why doctors often start low and raise the dose gradually. For many people these ease over the first one to two weeks as the body adjusts, though this varies. Some effects, like swelling (edema) or weight gain, can build up more gradually with continued use. Sources don't give a fixed day-by-day count, so treat any specific timeline as approximate. If drowsiness or dizziness stays strong, don't just quit — ask your prescriber, who may adjust the dose or timing.

"In your system" means two different things. First, how long the drug is active and clearing: gabapentin has an elimination half-life of about 5 to 7 hours in adults with normal kidney function (StatPearls). Because a drug is largely cleared after roughly 4 to 5 half-lives, that works out to about 20 to 35 hours — StatPearls states it takes about 2 days for the body to eliminate gabapentin. Gabapentin is unusual in that it is barely metabolized; it is removed almost entirely unchanged by the kidneys, so clearance tracks directly with kidney function. Second, how long a drug test can DETECT gabapentin: that window is longer than the clearance window and depends on the type of test (see below). These are approximate ranges from laboratory references, not guarantees.

Urine is the most common test, and gabapentin is typically detectable for about 1 to 3 days after the last dose, occasionally up to 4 days (Recovered.org). An important, honest point: gabapentin is NOT included on standard 5-panel or 12-panel drug screens, which look for opioids, cocaine, cannabis, amphetamines and the like. It only shows up when a lab specifically tests for it using GC-MS or LC-MS/MS. The exact window varies with dose, how long and how often it was taken, kidney function, hydration, and the specific assay and its cutoff. Only the testing lab can interpret a specific result.

These windows differ by sample type (typical ranges from Recovered.org): blood is the shortest, roughly 5 to 24 hours, reflecting gabapentin's short 5-to-7-hour half-life; saliva is detectable for up to about 2 days; and hair testing can reflect use for up to about 90 days, because drugs deposit into the growing hair shaft and give a much longer look-back. As with urine, hair and specialized blood/saliva testing for gabapentin require a targeted lab assay — it is not part of routine panels. All figures are approximate.

Several factors shift the range: dose and frequency (a single dose clears faster than chronic daily use of 900 to 1,800 mg or more); kidney function, since gabapentin is eliminated almost entirely by the kidneys and reduced kidney function slows clearance substantially; age, which often tracks with kidney function; body composition and hydration; and the specific test's cutoff level and technology. Because of the kidney-clearance dependence, elimination correlates directly with creatinine clearance (StatPearls). These are approximate ranges from laboratory references, not guarantees — only a clinician or the testing lab can interpret a specific result, and you should not stop or change a prescribed medication based on this information.

The FDA has approved Neurontin (gabapentin) for two uses: relieving postherpetic neuralgia — the burning, stabbing nerve pain that can last months or years after a shingles attack — and, as an add-on to other medications, controlling partial-onset (focal) seizures in adults and children 3 and older. Beyond those, doctors prescribe gabapentin off-label (a legal, common practice that means the FDA has not formally approved it for that use, not that it is unproven). MedlinePlus documents off-label use for diabetic neuropathy pain and for hot flashes; in wider clinical practice it is also used for other nerve pain, restless legs, anxiety, and alcohol withdrawal, though those specific uses go beyond what the FDA label and MedlinePlus formally list. Note that a related extended-release product, Horizant (gabapentin enacarbil), is separately FDA-approved for restless legs syndrome, but Neurontin itself is not. This is not a complete list — ask your prescriber or pharmacist about your specific situation, and never start or stop a prescription on your own. (Sources: FDA prescribing information; MedlinePlus, gabapentin.)

For nerve pain: yes. Gabapentin is FDA-approved for one specific type — postherpetic neuralgia (nerve pain after shingles) — and is widely used off-label for other neuropathic pain, most commonly diabetic neuropathy. That off-label use is common and supported by clinical evidence, even though the FDA has not formally approved gabapentin for it. For anxiety: gabapentin is used off-label only — it is not FDA-approved for any anxiety disorder, and the evidence is mixed, with some support for certain situations but no consensus that it is a first-line treatment. If anxiety or nerve pain is the reason you are considering it, that decision belongs with a prescriber who can weigh the evidence for your case; do not start or stop it on your own. (Sources: FDA prescribing information; MedlinePlus, gabapentin.)

Yes — gabapentin is the generic drug and Neurontin is a brand name for it, so "Neurontin" and "generic gabapentin" contain the same active ingredient at the same strengths. Prices differ (the generic is usually far cheaper), but the FDA-approved uses are identical: postherpetic neuralgia and add-on treatment of partial-onset seizures. Be aware that "gabapentin" also comes in other branded formulations that are approved for different things — for example Horizant (extended-release gabapentin enacarbil) for restless legs syndrome and Gralise for postherpetic neuralgia — so the specific product matters. Your pharmacist can confirm which formulation you have. (Source: FDA prescribing information.)